Get the Stockscreener App
2.47
2.92%
0.07
Gossamer Bio Inc stock is traded at $2.47, with a volume of 2.53M.
It is up +2.92% in the last 24 hours and up +26.02% over the past month.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
See More
Previous Close:
$2.40
Open:
$2.41
24h Volume:
2.53M
Relative Volume:
0.95
Market Cap:
$561.63M
Revenue:
-
Net Income/Loss:
$-179.82M
P/E Ratio:
-1.8571
EPS:
-1.33
Net Cash Flow:
$-159.16M
1W Performance:
+5.56%
1M Performance:
+26.02%
6M Performance:
+107.56%
1Y Performance:
+186.91%
1-Day Range:
$2.375
$2.50
1-Week Range:
$2.27
$2.645
52-Week Range:
$0.6617
$2.645
Gossamer Bio Inc Stock (GOSS) Company Profile
Name
Gossamer Bio Inc
Sector
Industry
Phone
(858) 684-1300
Address
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
2.47 | 545.71M | 0 | -179.82M | -159.16M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-14-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-05-24 | Resumed | Wedbush | Outperform |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Mar-07-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-01-23 | Initiated | Guggenheim | Neutral |
| Dec-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-07-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-07-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | JP Morgan | Neutral |
| Sep-19-22 | Initiated | Wedbush | Outperform |
| Apr-18-22 | Initiated | Raymond James | Outperform |
| Apr-06-22 | Initiated | UBS | Buy |
| Jan-10-22 | Upgrade | SMBC Nikko | Neutral → Outperform |
| Nov-09-21 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-21-21 | Resumed | Piper Sandler | Overweight |
| Jun-29-20 | Initiated | H.C. Wainwright | Buy |
| Apr-22-20 | Initiated | Piper Sandler | Overweight |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-30-19 | Initiated | Berenberg | Buy |
| Mar-05-19 | Initiated | Barclays | Overweight |
| Mar-05-19 | Initiated | BofA/Merrill | Buy |
| Mar-05-19 | Initiated | Evercore ISI | Outperform |
| Mar-05-19 | Initiated | SVB Leerink | Outperform |
View All
Gossamer Bio Inc Stock (GOSS) Latest News
Momentum divergence signals in Gossamer Bio Inc. chart2025 Institutional Moves & Consistent Profit Trade Alerts - Newser
Is Gossamer Bio Inc. reversing from oversold territoryBull Run & Risk Controlled Stock Pick Alerts - Newser
Using R and stats models for Gossamer Bio Inc. forecasting2025 Year in Review & Free Expert Verified Stock Movement Alerts - Newser
What high frequency data says about Gossamer Bio Inc.Trade Entry Summary & Safe Entry Point Identification - Newser
Multi asset correlation models including Gossamer Bio Inc.Risk Management & Consistent Income Trade Recommendations - Newser
Is Gossamer Bio Inc. building a consolidation baseTrend Reversal & AI Enhanced Execution Alerts - Newser
Is Gossamer Bio Inc. stock poised for growth2025 Analyst Calls & Fast Moving Market Watchlists - Newser
Technical analysis overview for Gossamer Bio Inc. stockBull Run & Technical Confirmation Trade Alerts - Newser
Using AI based signals to follow Gossamer Bio Inc.Weekly Trade Review & Free High Accuracy Swing Entry Alerts - Newser
What the charts say about Gossamer Bio Inc. todayAnalyst Upgrade & Expert Curated Trade Setups - Newser
Should you wait for a breakout in Gossamer Bio Inc.2025 Volume Leaders & Reliable Entry Point Alerts - Newser
How hedge fund analytics apply to Gossamer Bio Inc. stockJuly 2025 Big Picture & Weekly High Return Stock Forecasts - Newser
Can Gossamer Bio Inc. hit a new high this monthJuly 2025 Gainers & Stepwise Trade Signal Implementation - Newser
Analyzing Gossamer Bio Inc. with multi timeframe chartsJuly 2025 Volume & Consistent Profit Trading Strategies - Newser
Does Gossamer Bio Inc. qualify in momentum factor screeningJuly 2025 Intraday Action & Verified Swing Trading Watchlists - Newser
Sector ETF performance correlation with Gossamer Bio Inc.Market Volume Summary & Weekly Momentum Stock Picks - Newser
Using Python tools to backtest Gossamer Bio Inc. strategies2025 Dividend Review & Community Shared Stock Ideas - Newser
Short interest data insights for Gossamer Bio Inc.July 2025 Macro Moves & Community Supported Trade Ideas - Newser
What machine learning models say about Gossamer Bio Inc.July 2025 Fed Impact & Stock Portfolio Risk Management - Newser
Why Gossamer Bio Inc. is moving todayJuly 2025 Review & Technical Analysis for Trade Confirmation - Newser
How to read the order book for Gossamer Bio Inc.Gap Down & High Yield Equity Trading Tips - Newser
Should you hold or exit Gossamer Bio Inc. nowWeekly Profit Summary & Weekly Momentum Picks - Newser
Analyzing recovery setups for Gossamer Bio Inc. investorsJuly 2025 Sentiment & AI Based Buy/Sell Signal Reports - Newser
Regression analysis insights on Gossamer Bio Inc. performanceJuly 2025 Reactions & Accurate Buy Signal Alerts - Newser
Heatmap analysis for Gossamer Bio Inc. and competitors2025 Momentum Check & AI Enhanced Execution Alerts - Newser
Gossamer Bio to Present at Upcoming Investor Conferences | GOSS Stock News - GuruFocus
PAH Drug Developer Gossamer Bio Set for Key Presentations at Cantor, Wells Fargo, HC Wainwright Events - Stock Titan
Will Gossamer Bio Inc. continue its uptrendMarket Performance Recap & Reliable Breakout Forecasts - Newser
How sentiment analysis helps forecast Gossamer Bio Inc.Swing Trade & Free Reliable Trade Execution Plans - Newser
Here’s What the Wall Street Thinks About Gossamer Bio (GOSS) - Insider Monkey
Gossamer Bio Inc Stock (GOSS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):